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Abstract
 .We assessed the effect of sulindac sulfide SS , a colon cancer chemopreventive agent, on the proliferation and apoptosis
in the colon cancer cell lines HCT-15 and HT-29. We applied a triparameter flow cytometric analysis that simultaneously
 .determined DNA content, expression of Ki-67 or proliferating cell nuclear antigen PCNA , and extent of DNA strand
 .breaks by TUNEL TdT-mediated dUTP nick end labeling . HCT-15 and HT-29 cells were exposed to SS 200 mM and
175mM, respectively, for up to 72 h. As expected, SS inhibited proliferation and induced apoptosis. SS also induced several
subpopulations of cells defined by their expression of proliferation markers and DNA strand breaks. By 72 h the rapidly
w  .  .xproliferating cells PCNArKi-67 q rTUNEL y were reduced from )90% to about one third. Of the remaining cells,
w  .  .x wabout one third were apoptotic PCNArKi-67 y rTUNEL q and one third were quiescent PCNArKi-
 .  .x  .  .67 y rTUNEL y . Another subpopulation was detected that was PCNArKi-67 q rTUNEL q , some had a dominant
subdiploid peak and over half were in S or G rM phases by DNA content. Thus, a subpopulation of apoptotic cells strongly2
expressed PCNA and Ki-67, suggesting that their specificity as proliferation markers may need reassessment. Similar results
were obtained with the HL-60 promyelocytic cell line. q 1997 Elsevier Science B.V.
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1. Introduction
One of the most remarkable advances in the pre-
vention of colon cancer is the appreciation of the
Abbreviations: SS, sulindac sulfide; NSAIDs, nonsteroidal
antiinflammatory drugs; PCNA, proliferating cell nuclear antigen;
TUNEL, TdT-mediated dUTP nick end labeling; 7AAD, 7-
amino-actinomycin D; TdT, terminal deoxynucleotidyl trans-
ferase; BSA, bovine serum albumin; PBS, phosphate buffered
saline
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prophylactic effect of nonsteroidal antiinflammatory
 .drugs NSAIDs . Animal, clinical and epidemiologi-
cal observations have documented the ability of these
compounds to not only reduce the incidence of and
mortality from colon cancer, but also, in some cases,
to regress already formed tumors. It is, therefore,
understandable that an intense effort is underway to
determine the mechanisms by which they bring about
this effect.
Sulindac, and its metabolites, such as sulindac
 .sulfide SS , produce a wide range of effects on cells
that could be useful in colon cancer prevention. Their
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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mechanism of action has been studied by our labora-
tory and others. It is now well documented that these
compounds exert two powerful effects on cultured
 .colon cancer cells; they: 1 inhibit cell proliferation,
 . w xand 2 induce cell death by apoptosis 1,2 . The
apoptotic effect has also been documented in the
mucosa of patients with familial adenomatous poly-
w xposis treated with oral sulindac 3 .
Both proliferation and apoptosis are critical deter-
minants of the growth of a tumor. Indeed, the growth
rate of tumors is determined by the proliferation rate
and by the rate of death of the tumor cells. Besides its
significance for tumor biology, the proliferation rate
is an important prognostic indicator for various can-
w xcers, including colon cancer tissues 4 .
The proliferation rate of tumors has been moni-
tored by using various proliferation markers. Promi-
nent among the proliferation markers are the Ki-67
w xantigen 5–9 and proliferating cell nuclear antigen
 . w xPCNA 10–15 . The Ki-67 antigen, which is de-
w xtected in all phases of the cell cycle except in G 7 ,0
proved excellent for the estimation of the growth
fraction in a wide variety of normal and malignant
w xhuman tissues, including colon 16 . The MIB-1 anti-
body, frequently used in such studies, was generated
w xagainst recombinant parts of the Ki-67 antigen 17 .
PCNA, an auxiliary protein to DNA polymerase E
w x18 , functions as a co-factor in DNA synthesis. The
synthesis and expression of PCNA are enhanced in
w xproliferating cells 19 . PCNA has been considered as
the most reliable method to evaluate proliferation in
w xcolon tissues 4 .
Apoptotic cell death, a process of gene directed
w xself-destruction 20,21 , can affect the cell number in
a tissue. Apoptosis involves activation of endonucle-
ases which causes DNA strand breaks and, ulti-
w xmately, DNA fragmentation in situ 22 . In this con-
text as well, DNA damage and repair are of funda-
mental importance for the continued survival of the
w xcell 23 .
As we were studying the mechanism of the apop-
totic and anti-proliferative effects of SS, we obtained
data suggesting that Ki-67 and PCNA may be ex-
 .pressed in apoptotic dying cells. This discovery
 .could have wider implications for a the mechanism
 .of action of SS, and b the utility of these antigens as
proliferation markers. Because of these considera-
tions, we undertook a detailed study of this prelimi-
nary observation. The results of our work are pre-
sented in this paper.
2. Materials and methods
2.1. Cell lines
The human colon adenocarcinoma cell lines HT-29
and HCT-15 cells and the promyelocytic leukemia
cell line HL-60 were obtained from American Type
 .Culture Collection ATCC, Rockville, MD , and
grown according to the instructions of ATCC. HCT-
15 cells and HL-60 cells were cultured in RPMI
1640, and HT-29 cells in McCoy 5A GIBCO, Grand
.Island, NY media, which were supplemented with
10% fetal calf serum Gemini Bio-Products, Cal-
.  .abasas, CA , streptomycin 10 000 Urml and peni-
 .cillin 10 000 Urml . Cells were incubated at 378C in
a humidified atmosphere of 5% CO in air. Cells2
were seeded at a density of 1=106 cells per 100 cm2
 .culture dish Falcon, Becton-Dickinson, NJ .
2.2. Reagents
Sulindac sulfide desoxy-sulindac, generously pro-
.vided by Merck, Rahway, NJ , was dissolved in
 .DMSO Fisher Scientific, Fair Lawn, NJ . All com-
pounds were added to the culture medium and cells
prior to plating. The DMSO concentration was ad-
justed to 0.6% in all SS-supplemented media. The
experiments were carried out with 2 independently
prepared batches of SS. The batch used for HT-29
cells had optimal activity at 175mM, whereas the
batch used for the HCT-15 experiment had optimal
activity in both cell lines at 200 mM.
2.3. Tricolor flow cytometric analysis
A tricolor flow cytometric staining technique was
used in which DNA content was determined by 7-
 . amino-actinomycin D 7AAD Sigma, St. Louis,
.MO staining, Ki-67 and PCNA expression by phyco-
erythrin-conjugated mAbs, and DNA cleavage by the
tailing reaction known as TUNEL TdT-mediated
.dUTP nick end labeling , where fluorescein labels are
incorporated in nucleotide polymers. Each of these
procedures are described below.
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2.4. Immunofluorescent staining for DNA strand
( )breaks TUNEL
Cells were harvested by using 0.05%
 .trypsinrEDTA GIBCO and then resuspended in 1%
 .bovine serum albumin BSA in phosphate buffered
 .  .saline PBS PBSrBSA . Aliquots of cells were
counted using a hemacytometer and tested for viabil-
 .ity by the trypan-blue dye Sigma exclusion method.
Cells that stained blue were considered ‘‘non-viable’’.
 6.Cells 2=10 were washed with 1% PBSrBSA
 .and fixed in 200 ml 2% paraformaldehyde pH 7.4 in
PBS for 15 min at 48C. Cells were washed with
PBSrBSA and incubated with 0.1% Triton-X 100 in
PBS for 5 min on ice. A one-step procedure to detect
w xDNA strand breaks was employed 24,25 , using a
commercial kit Boehringer Mannheim, Indianapolis,
.IN ; DNA strand breaks indicated apoptotic cells. In
the procedure, the Enzyme Solution contained termi-
 .nal deoxynucleotidyl transferase TdT and the Label
Solution contained the labeled nucleotide in reaction
buffer 3 nmol FITC-dUTP, 2 ml 25 mM CoCl and2
TdT buffer 30 mM Tris pH 7.2, 140 mM sodium
.cacodylate . The cells were washed with PBS and
resuspended in 50 mlrtube TUNEL Reaction Mixture
50 ml of Enzyme Solution plus 450 ml of Label
.Solution . Omission of TdT provided the negative
control. Cells were incubated for 60 min at 378C in a
humidified atmosphere in the dark, washed with
PBSrBSA and processed according to any of the
following procedures.
2.5. Immunocytochemical staining for Ki-67 and
PCNA
Following the above procedures, cells were incu-
bated for 60 min at room temperature in the presence
 .  .of primary antibodies: PCNA PC-10 diluted 1:200 ,
 .  .PharMingen, San Diego, CA ; MIB-1 anti-Ki-67 ,
 .diluted 1:100, Oncogene Sciences, Uniondale, NY ;
Nonspecific IgG and IgG which are the isotypic1 2a
controls for PC-10 and MIB-1, respectively Becton-
.Dickinson . Cells were then washed and incubated
with goat-anti-mouse-phycoerythrin antibody diluted
1:50, Jackson Immuno Research Lab, West Grove,
.PA for 60 min at room temperature in the dark. Cell
were washed again with PBSrBSA, resuspended in
10 mgrml 7AAD in PBS and incubated at room
temperature for 1 h prior to measurement.
2.6. Flow cytometry
Flow cytometry was performed using a Coulter
Profile XL equipped with a single argon ion laser and
 .  .  .FL1 FITC ; FL2 phycoerythrin ; FL3 7AAD filter
combination. Minimal electronic compensation was
used. The spectral properties of fluorescent probes
w xwere described previously 26 . A minimum of 10 000
events were collected for the particular subset ana-
lyzed for tricolor staining. All parameters Linear
FSC, Log SSC, Log of FITC, phycoerythrin and
.linear of 7AAD were collected in listmode files.
Data were further analyzed on an XL Elite Work
 .station Coulter .
3. Results
In this study we wished to assess the effect of
sulindac sulfide on the status of DNA and the interre-
lationship of proliferation markers and apoptosis in
colon cancer cells. To this end we first confirmed the
 .anticipated effect of this compound on the kinetics
of our cell lines, then described the expression of
proliferation markers in relationship to DNA frag-
 .mentation TUNEL positivity , and finally we as-
sessed the effect of SS on these parameters.
3.1. Sulindac sulfide reduces the proliferation, alters
the cell cycle distribution and induces apoptosis in
HT-29 and HCT-15 colon cancer cells
2=106 HCT-15 or HT-29 colon cancer cells were
exposed to sulindac sulfide at 200 mM and 175mM,
respectively, for up to 72 h. In agreement with our
w xprevious observations 1,2 , SS dramatically reduced
the proliferation of both cell lines. At 72 h, the num-
ber of HCT-15 cells was 10% of the control, and of
HT-29 20% of the control. In both cell lines this
effect was evident at 24 h and became maximal at
72 h.
Table 1 illustrates the effect of SS on cell cycle
distribution of both cell lines. HCT-15 cells had no
significant changes after treatment with SS. In con-
trast, the cell cycle distribution of HT-29 cells was
( )L. Qiao et al.rBiochimica et Biophysica Acta 1359 1997 222–232 225
Table 1
The effect of sulindac sulfide on cell cycle distribution of HT-29
and HCT-15 colon cancer cells
Cell cycle phases G S G rM1 2
HT-29 cells
Control 53% 35% 12%
Sulindac sulfide 87 8 5
HCT-15 cells
Control 50 38 12
Sulindac sulfide 50 39 11
HCT-15 and HT-29 cells were treated with sulindac sulfide
200 mM and 175mM, respectively, for 72 h. The percentage of
cells in each phase of the cell cycle was determined by 7AAD
staining, as described in Section 2. This protocol was followed
three times and values each time were within 5%.
clearly altered by SS: the proportion of cells in G1
phase was increased and that in S and G rM phases2
was decreased.
3.2. The presence of DNA strand breaks and the
expression of proliferation markers define four popu-
lations of colon carcinoma cells
We employed a flow cytometric analysis of colon
cancer cells that provided the simultaneous assess-
 .ment of the following three parameters: a the ex-
pression of either Ki-67 or PCNA proliferation anti-
 . gens; b the presence of DNA strand breaks endo-
.  .nucleolysis , assessed by the TUNEL method, and c
the distribution of the DNA content in the cell cycle,
 .including the presence of the subdiploid apoptotic
peak.
HCT-15 or HT-29 cells, plated in 100 cm2 plates,
were harvested 24, 48 and 72 h later and subjected to
the triparametric analysis by flow cytometry. The
type of results that were obtained are shown in Figs.
1 and 2; the relationship between DNA strand breaks
Fig. 1. DNA strand breaks and PCNA expression in HCT-15 colon carcinoma cells treated with sulindac sulfide. Cells were stained for
 .  .PCNA and labeled with TUNEL, as in Section 2. Dot plots of TUNEL ordinate vs. PCNA abscissa are shown. Region 1,
 .  .  .  .  .  .  .  .TUNEL q rPCNA y ; Region 2, TUNEL q rPCNA q ; Region 3, TUNEL y rPCNA y ; Region 4, TUNEL y rPCNA q .
 .Panel A: the untreated cells were stained with TUNEL control solution and IgG PCNA isotypic control . Panel B: untreated cells were2a
stained with TUNEL and PCNA. Panel C: cells treated with SS 200 mM for 48 h were stained with TUNEL control solution and IgG .2a
Panel D: cells treated with SS 200 mM for 48 h were stained with TUNEL and PCNA.
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Fig. 2. DNA strand breaks and Ki-67 expression in HCT-15 colon carcinoma cells treated with sulindac sulfide. Cells were stained for
 .  .Ki-67 and labeled with TUNEL, as in Section 2. Dot plots of TUNEL ordinate vs. Ki-67 abscissa are shown. Region 1,
 .  .  .  .  .  .  .  .TUNEL q rKi-67 y ; Region 2, TUNEL q rKi-67 q ; Region 3, TUNEL y rKiy67 y ; Region 4, TUNEL y rKi-67 q .
 .Panel A: the untreated cells were stained with TUNEL control solution and IgG Ki-67 isotypic control . Panel B: untreated cells were1
stained with TUNEL and Ki-67. Panel C: cells treated with SS 200 mM for 48 h were stained with TUNEL control solution and IgG1.
Panel D: cells treated with SS 200 mM for 48 h were stained with TUNEL and Ki-67.
and the expression of proliferation markers PCNA or
.Ki-67 can be assessed. The four regions, 1–4, were
saved in listmode files. Region 3 was defined by the
sample that represented the negative controls for both
  .TUNEL and PCNA or Kiy67 antigen Fig. 1 A
 ..and Fig. 2 A .
Based on the expression of these antigens and the
presence of DNA strand breaks, untreated HCT-15
and HT-29 cells could be separated into four subpop-
wulations of cells, as described below see also Figs. 1
 .  .and 2 HCT-15 ; Table 2 HCT-15 and Table 3
 .xHT-29 .
1. Cells that do not express proliferation markers and
wshow DNA strand breaks PCNA or Ki-67
 .  .xy rTUNEL q . These cells are 0.1–2% of the
  .  ..total region 1, Fig. 1 B and Fig. 2 B . They are
apoptotic cells.
2. Cells that express proliferation markers and show
wDNA strand breaks PCNA or Ki-67
 .  .q rTUNEL q . These cells are 1–1.7% of the
  .  ..total region 2, Fig. 1 B and Fig. 2 B . The
significance of this population is not conspicu-
ously apparent.
3. Cells that do not express proliferation markers and
whave no detectable DNA strand breaks PCNA or
 .  .xKi-67 y rTUNEL y . They are 4–17% of the
  .  ..total region 3, Fig. 1 B and Fig. 2 B . These are
probably cells that have entered a stationary or
quiescent phase, possibly following the logarith-
mic growth.
4. Cells that express proliferation markers and have
wno detectable DNA strand breaks PCNA or Ki-67
 .  .xq rTUNEL y . These cells are G80% of the
  .  ..total region 4, Fig. 1 B and Fig. 2 B . They
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Table 2
 .DNA strand breaks and the expression of proliferation markers in HCT-15 colon cancer cells treated with sulindac sulfide SS
Time 24 h 48 h 72 h
 .  .  .  .  .  .PCNA q PCNA y PCNA q PCNA y PCNA q PCNA y
( )TUNEL q
Control 2% 0.2% 3% 0.3% 1.7% 0.4%
SS 12 7 28 7 38 4
( )TUNEL y
Control 93 4 94 3 81 17
SS 43 28 42 23 32 26
 .  .  .  .  .  .Ki-67 q Ki-67 y Ki-67 q Ki-67 y Ki-67 q Ki-67 y
( )TUNEL q
Control 3 2 3 0.2 1 0.7
SS 2.5 0.7 13 12 20 12
( )TUNEL y
Control 91 3 94 3 83 15
SS 80 16 43 32 24 44
DNA strand breaks were determined by the TUNEL assay and the expression of the proliferation markers PCNA and Ki-67 were assayed
by a triparameter flow cytometric analysis, as described in Section 2. This protocol was repeated three times and results were within 10%
of the values presented here.
represent the rapidly proliferating fraction of these
cells, which were in their growth phase.
We were able to determine the distribution of
DNA content in the cell cycle phases only for the last
population of cells, which provided the overwhelm-
ing majority of events on flow cytometry. For the
remaining untreated cells, the events were too few to
obtain an accurate DNA histogram. The role of popu-
lations 1 and 3 above was also deduced in conjunc-
tion with the changes that were observed after SS
 .treatment see below .
The expression of proliferation markers was time-
Table 3
 .DNA strand breaks and the expression of proliferation markers in HT-29 colon cancer cells treated with sulindac sulfide SS
Time 24 h 48 h 72 h
 .  .  .  .  .  .PCNA q PCNA y PCNA q PCNA y PCNA q PCNA y
( )TUNEL q
Control 2% 0.1% 2% 0.1% 1.7% 0.4%
SS 4.2 0.4 26 4 34 3.2
( )TUNEL y
Control 90 7 90 7 80 17
SS 55 40 45 25 34 28
 .  .  .  .  .  .Ki-67 q Ki-67 y Ki-67 q Ki-67 y Ki-67 q Ki-67 y
( )TUNEL q
Control 2 2 2 2 1 0.7
SS 2.5 0.7 29 8 37 6.8
( )TUNEL y
Control 91 4 91 4 83 15
SS 79 18 17 46 20 35
DNA strand breaks were determined by the TUNEL assay and the expression of the proliferation markers PCNA and Ki-67 were assayed
by a triparameter flow cytometric analysis, as described in Section 2. This protocol was repeated three times and results were within 10%
of the values presented here.
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dependent in untreated HCT-15 cells, as it decreased
by about 10% between 48 h and 72 h. This decrease
may reflect the fraction of cells that, during this time
period, started completing their logarithmic phase of
 .growth Fig. 3, bottom panels and Table 2 . Similar
results were obtained for HT-29 cells, as indicated in
Table 3.
3.3. The effect of sulindac sulfide on the four popula-
tions of colon cancer cells
Sulindac sulfide had a profound effect on the
distribution of HCT-15 cells in the four different
populations described above. Our findings, depicted
in Figs. 1–3 and Tables 2 and 3, are summarized
Fig. 3. The effect of sulindac sulfide on the subpopulations of
HCT-15 cells defined by TUNEL and PCNArKi-67. This figure,
based on the results shown in Tables 2 and 3, presents the
percentage changes of the various cell subpopulations after treat-
ment with SS for 24, 48, and 72 h. The definition of each
population is described in Section 2.
below. Treatment of HCT–15 cells with SS 200 mM
led to the following changes:
1. Increase in the proportion of cells that do not
express proliferation markers and show DNA
 .  .strand breaks. At 72 h the PCNA y rTUNEL q
 .cells increased to 4% of the total control: 0.4% ,
 .  .whereas those that were Ki-67 y rTUNEL q
 .increased to 12% of the total control: 0.7% .
2. Increase in the proportion of cells that express
proliferation markers and show DNA strand
 .  .breaks. At 72 h the PCNA q rTUNEL q cells
 .increased to 38% of the total control: 1.7% ,
 .  .whereas those that were Ki-67 q rTUNEL q
 .increased to 20% of the total control: 1% .
3. Increase in the proportion of cells that do not
express proliferation markers and have no de-
tectable DNA strand breaks. At 72 h the
 .  .PCNA y rTUNEL y cells increased to 26% of
 .the total control: 17% , whereas those that were
 .  .Ki-67 y rTUNEL y increased to 44% of the
 .total control: 15% . Of note, in this case the
changes were more pronounced at 48 h.
4. Decrease in the proportion of cells that express
proliferation markers and have no detectable DNA
 .  .strand breaks. At 72 h the PCNA q rTUNEL y
 .cells decreased to 32% of the total control: 81% ,
 .  .whereas those that were Ki-67 q rTUNEL y
 .decreased to 24% of the total control: 83% .
Overall, sulindac sulfide appears to have depleted
the pool of proliferating cells and enhanced the other
three populations of cells. This has been followed by
a modest increase in the population of stationary cells
 .proliferation marker and TUNEL negative cells .
However, the most significant shift of cells has taken
place towards the TUNEL positive cells proliferation
.marker positive and negative cells , which now com-
prise about half of all the cells.
HT-29 cells treated with SS 175mM displayed
 .similar changes as HCT-15 cells Table 3 .
3.4. Analysis of DNA content
To further characterize these populations of cells,
we used gating analysis to determine their DNA
distribution of HCT-15 cells. As demonstrated in Fig.
4, we were also able to study separately the two
distinct subpopulations of region 4 of the two-dimen-
 .sional histograms e.g., Fig. 4, panel A .
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Fig. 4. Gating flow cytometric analysis of DNA strand breaks, PCNA expression and DNA content in HCT-15 cells treated with sulindac
sulfide. HCT-15 cells were treated with SS 200 mM for 48 h and analyzed as in Section 2. Panel A shows the entire cell population
w  .  .xdistributed in four regions. The cells of gating region 1 TUNEL q rPCNA y displayed the subdiploid peak on DNA content analysis
 .shown in panel B. The distinct cell population in the upper left portion of region 2 Panel C, gated which showed stronger TUNEL
 .positivity, displayed a dominant subdiploid peak in the DNA histogram. The larger subpopulation of region 2 right lower portion
 .  .  .displayed a DNA histogram with prominent G , S and G rM and no subdiploid peak Panel D . Analysis of the TUNEL y rPCNA y1 2
 . w  .  .xregion 3, showed a prominent G rG phase panel E . The cells in region 4 TUNEL y rPCNA q showed G rG and S phases0 1 0 1
 .panel F . The relative distribution of cells in the different phases of the cell cycle, measured by DNA content, is as follows: Panel A:
 .Subdiploid SD s13%; G rG s50%; Ss39%; G rMs11%. Panel B: SDs6%; G rG s0%; Ss0%; G rMs0%. Panel C:0 1 2 0 1 2
SDs7%; G rG s0%; Ss0%; G rMs0%. Panel D: SDs0%; G rG s20%; Ss55%; G rMs25%. Panel E: SDs0%;0 1 2 0 1 2
G rG s100%; Ss0%; G rMs0%. Panel E: SDs0%; G rG s70%; Ss30%; G rMs0%.0 1 2 0 1 2
In the case shown in Fig. 4, HCT-15 cells were
treated with SS 200 mM for 48 h. Panel A shows that
when the entire population of SS-treated cells were
 .assessed for DNA content, there was the expected
apoptotic peak. Panel B shows that cells that
 .  .were TUNEL q rPCNA y manifested a domi-
nant apoptotic peak, without discernible G rG , S0 1
 .and G rM phases. Cells that were TUNEL q r2
 .PCNA q consisted of two subpopulations: one sub-
 .population 7% of all the cells contained cells that
 .were more strongly TUNEL q and showed a domi-
nant subdiploid apoptotic peak on DNA content anal-
 . ysis panel C ; the other subpopulation 21% of all
.  .the cells , which was less strongly TUNEL q , con-
sisted of cells with no subdiploid apoptotic peak and
DNA content consistent with S and G rM phases of2
 .the cell cycle panel D . Cells that were
 .  .TUNEL y rPCNA y had a prominent G rG0 1
peak and almost nonexistent S and G rM peaks2
 .  .panel E . Finally, cells that were TUNEL y r
 .PCNA q showed DNA content mainly in G rG0 1
and S phases, with few cells in the G rM phase.2
 .These findings indicate that the TUNEL q r
 .PCNA q cell population, the one most prominently
increased by SS, was heterogeneous. As evidenced
by their DNA content, some of these cells were
clearly apoptotic by DNA content criteria, whereas
the rest displayed prominent S and G rM phases.2
The latter were about three-fold greater than the
former. Similar results were obtained for HCT-15
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cells at 72 h and also in the case of HT-29 cells data
.not shown .
3.5. Sulindac sulfide induces similar changes in HL-
60 promyelocytic leukemia cells
To ascertain whether these findings are restricted
to colonic cells, we evaluated the effect of sulindac
sulfide on the HL-60 promyelocytic leukemia cell
w xline. As we have already shown 1 , SS induces
apoptosis in these cells as well. HL-60 cells were
treated with SS 175mM for 4 h, as previously de-
scribed.
Table 4 shows the triparameter flow cytometric
analysis of these cells for DNA strand breaks
 .TUNEL , PCNA or Ki-67 expression, and DNA
content. Again, four populations of cells are identi-
fied, based on TUNEL positivity and PCNArKi-67
expression, in the same manner that was used in
analyzing HT-29 and HCT-15 cells.
Similar to the findings in the two colon cell lines,
SS significantly affects the distribution of HL-60
cells in these four populations. Particularly important
is the increase in the cells that expressed proliferation
markers and displayed DNA strand breaks,
 .  .  .  .TUNEL q rKi-67 q or TUNEL q rPCNA q ,
Table 4
DNA strand breaks and the expression of proliferation markers in
HL-60 promyelocytic leukemia cells treated with sulindac sulfide
 .  .PCNA q PCNA y
( )TUNEL q
Control 5% 0.1%
Sulindac sulfide 24 8
( )TUNEL y
Control 87 7
Sulindac sulfide 21 47
 .  .Ki-67 q Ki-67 y
( )TUNEL q
Control 5 1
Sulindac sulfide 28 4
( )TUNEL y
Control 72 22
Sulindac sulfide 42 26
The cells were treated with sulindac sulfide for 4 h. DNA strand
breaks were determined by the TUNEL assay and the expression
of the proliferation markers PCNA and Ki-67 were assayed by a
triparameter flow cytometric analysis, as described in Section 2.
This protocol was repeated twice and results were within 5% of
the values presented here.
and the decrease in those cells that express prolifera-
tion markers but show no evidence of DNA strand
 .  .  .breaks, TUNEL y rKi-67 q and TUNEL y ri
 .  .  .PCNA q . Also, the TUNEL q rPCNA q cells
consisted of two subpopulations, one comprised of
apoptotic cells and the other of cells with prominent
S and G rM peaks.2
These findings clearly indicate that the type of
response to sulindac sulfide obtained with the colon
cells also takes place in the non-colonic cells such as
leukemia cells.
4. Discussion
The findings of our present study provide insights
into the effect of sulindac sulfide on colon cancer
cells. First, they document the redistribution of cells
among several different subpopulations, defined by
the expression of proliferation markers and DNA
strand breaks. And, second, they suggest that some
clearly apoptotic cells can strongly express the prolif-
eration markers PCNA and Ki-67.
Study of the two cell lines, HT-29 and HCT-15,
with the triparameter flow cytometric analysis pro-
vided the simultaneous assessment of three important
parameters, namely the expression of one prolifera-
tion marker, the extent of DNA strand breaks and
also the DNA content of the cells. This approach
permitted not only the unambiguous definition of
several cell subpopulations but also the quantitative
monitoring of the distribution of cells among them in
response to SS treatment. This was not possible with
assessment of these parameters separately as was
done in our previous studies.
As one might expect, the overwhelming majority
 .of control i.e., untreated cells in logarithmic growth
w  .were actively proliferating PCNArKi-67 q r
 .x wTUNEL y , with few in quiescence PCNArKi-
 .  .x67 y rTUNEL y ; an insignificant fraction of cells
 . w- 2% were either apoptotic PCNArKi-
 .  .x67 y rTUNEL q or had both DNA strand breaks
and strong expression of proliferation markers
w  .  .xPCNArKi-67 q rTUNEL q .
Sulindac sulfide profoundly altered the distribution
of colon cancer cells among these four populations.
First, it depleted significantly the proliferating frac-
w  .  .xtion of cells PCNArKi-67 q rTUNEL y . This
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finding is in agreement with the antiproliferative
w xeffect of SS, which has been previously described 1
and was also documented in this study.
The second effect was the expected induction of
apoptosis. Based on TUNEL positivity, over 30% of
the cells are apoptotic. Further study of the
 .TUNEL q cells on the basis of their DNA content,
indicates that about 14% of the total at 48 h, had a
 .subdiploid apoptotic peak. This number is consis-
w xtent with previously published data 1,2 . That apop-
totic cells express PCNA may be consistent with the
reported role of PCNA in apoptosis. Sustained high
levels of PCNA in conjunction with an arrest of the
cell in G rS might be or might reflect one of the1
early signals for the cells to enter an apoptotic cycle
w x27 .
The third effect was the increase in the population
of quiescent cells. By 72 h, roughly one fourth
w  .  .xPCNA y rTUNEL y to a little less than half
w  .  .xKi-67 y rTUNEL y of the cells were quiescent.
This represents a quantitatively major effect of SS on
these cells, which contributes to its antiproliferative
effect. Our previous analysis, based on determination
of the DNA content of these cells and the expression
of cell cycle regulatory proteins, detected but could
w xnot quantify this effect 1,28 .
It appears that, as we described, sulindac sulfide
reduces the final number of colon cancer cells by two
effects: the induction of apoptosis and the induction
of cell quiescence. Roughly, these two effects are
quantitatively equivalent, with about one third of the
cells becoming quiescent and another third becoming
apoptotic. It is of interest that there was a marked
difference in the effect of sulindac sulfide on the cell
cycle distribution of the two cell lines we studied.
While HT-29 cells arrested with diploid DNA con-
tent, HCT-15 cells retained their cell cycle distribu-
tion after treatment with this NSAID compound. It is
conceivable that HCT-15 cells became ‘‘quiescent,’’
i.e., lost expression of proliferation markers, while
maintaining their DNA content. The reasons for this
difference remain unclear. Although both cell lines
are derived from colon cancers, they differ, for exam-
ple, in their genetic makeup, and in their ability to
differentiate. HT-29 cells can differentiate in re-
sponse to butyrate and glucose withdrawal, whereas
HCT-15 cells show a limited response to such agents
w x .28,29 and unpublished observations .
Our results suggest that there may exist yet another
 .  .category of cells, PCNA q rTUNEL q . Of these,
two subgroups can be distinguished, depending on
the intensity of TUNEL and PCNA staining. The
cells of the first group, representing about one-quarter
of the total, exhibit strong TUNEL and weak PCNA
staining and a prominent subdiploid peak Fig. 4,
. Panel C . The cells of the second group three quar-
.ters of the total are weakly TUNEL-positive and
strongly PCNA positive, have no appreciable sub-
diploid peak, and exhibit prominent S and G rM2
phase DNA contents. The cells in the first group are
apoptotic where PCNA may be functioning in its role
in DNA repair. The second group may represent cells
in a very early stage of apoptosis when the DNA is
beginning to be broken down by an endonucleolytic
mechanism activated in the context of apoptosis. It is
important to note that PCNA is associated with both
w xDNA replication and DNA repair 23,30 . PCNA
levels are elevated in response to DNA damage in
w xvivo 31 ; and the protein relocalizes to sites of DNA
w xrepair following damage in vitro 32,33 . However,
Ki-67 may not be required for DNA excision repair,
its expression being associated only with replicative
w xDNA synthesis 31 .
That these effects of sulindac sulfide were mani-
fest in two different colon cancer cell lines and in one
promyelocytic cell line, suggests that they may repre-
sent a more general activity of this versatile com-
pound. Of further interest is that, in contrast to
HT-29, the HCT-15 colon cancer cell line does not
express either one of the cyclooxygenases COX-1 or
.COX-2 . Since these effects of SS are virtually indis-
tinguishable in these two colon cell lines, it is un-
likely that SS acts via its well recognized inhibition
of prostaglandin synthesis. Alternative mechanisms
must be sought, in accord similar notions concerning
w xthe NSAIDs 2 .
The final important finding of our current work is
that colon cancer and promyelocytic cells can be
apoptotic and yet express the proliferation markers
PCNA and Ki-67. Our triparameter flow cytometric
analysis leaves no doubt that this is indeed the case;
the apoptotic peak in DNA content histograms was
the dominant component in cells expressing these
markers. Though the reason for this is not entirely
clear.
The presence of significant amounts of either Ki-67
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or PCNA in apoptotic cells calls into question their
specificity as proliferation markers. Our data indicate
that their specificity may be limited in cases where
apoptosis has been induced in cultured cells. How-
ever, it is consistent with the work of others that
showed that proliferation markers, such as BrdU
w xincorporation, can coexist in apoptotic cells 34 .
Further work will be required to examine whether
this is the case in tissues as well, or under the
influence of additional apoptotic stimuli.
In conclusion, our data provide insight into the
balance between the antiproliferative and apoptotic
effect of the NSAID sulindac sulfide in cultured cells
and indicate that apoptotic cells may strongly express
the proliferation biomarkers Ki-67 and PCNA, thus
suggesting that their specificity as proliferation mark-
ers may need to be re-assessed.
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